The past week's data-point-of-consequence for investors had to be investment decisions by Warren Buffett's Berkshire Hathaway (BRK.A).

Buffett ended positions in several stocks in the fourth quarter, including the Bank of America (BAC), Nike (NKE), Fiserv (FISV), Becton Dickinson (BDX), Comcast Corp. (CMCSA), Lowe's Co.s (LOW), Nalco (NLC) and Nestle (NSRGY), according to a filing, The Wall Street Journal reported.

Berkshire added to a holding of only one stock in the fourth quarter: Wells Fargo (WFC).

Analyst Upgrades

• FBR Capital upgraded Franklin Resources (BEN) to outperform from market perform and raised its target price for shares to $127 from $105 to reflect its belief the company is well positioned in the current environment.
• UBS upgraded Nuance (NUAN) to buy from neutral and has an $18 price target on the stock. The firm upgraded shares based on valuation and believes the company could be an acquisition target.
• Morgan Stanley upgraded DryShips (DRYS) to equal weight from underweight and has a $5.50 target on the stock. The firm cites the firmer ultra-deepwater drilling market for the upgrade.
• Becton Dickinson (BDX) was upgraded to neutral from sell at Goldman.
• Edwards Lifesciences (EW) was upgraded to market perform at Rodman & Renshaw.
• Arkansas Best (ABFS) was upgraded to neutral from underperform at BofA/Merrill.

Option traders appear to be setting up for a bullish move on CA Technologies (CA). Traders plowed into 4,799 new call option contracts -- 13.87 times the average volume -- on the stock on Thursday. And we know that traders were eager to get into this trade because 98% of the trades came in on the "ask" price.

CA Technologies closed Thursday at $18.13. The stock has dropped 7.64% during the past month, but it is currently sitting at support just above $18.

Health care stocks are seen as low-risk investments by many stock market investors. After all – folks will always get sick, right? While that may be the case, it's an oversimplification to say that all health care stocks then have a built in customer base. The fact of the matter is that the health care industry has seen a big shakeup in the wake of Obama's health care reform bill and not all stocks in this sector are adapting well.

To keep your portfolio in perfect health, here are three big-name health care blue chips to sell now.

Just call it a 'June Swoon' for Becton Dickinson and Co. (BDX), as the shares have dropped to about $69.50 from highs above $80 this spring. Even so, the business model, first discussed here on March 17, 2009 at a price of $65.66, remains preferred in these circles. Here's why:

In FY2010 Becton's revenue growth should total about 5-7%, after essentially flat revenue in FY2009. Hospital spending cutbacks will hurt, but BDX should make up for that with increased government orders, lower operating costs, and moderating raw material costs. Becton's medical and diagnostic units will also likely register revenue growth at or above 5-6% in 2010; its bioscience unit will register more-modest gains.

Analyst Upgrades

• FBR Capital upgraded Noble Corporation (NE) to outperform from market perform as it finds the company's acquisition of Frontier Drilling as smart and strategic. The firm upped its target price for shares to $42 from $36.
• Citigroup upgraded Ameriprise (AMP) to buy from hold, citing potential margin expansion from the Columbia acquisition. The firm maintains a $50 price target for shares.
• Thomas Weisel upgraded Jabil Circuit (JBL) to overweight from market weight, citing valuation and the company's growth prospects. The firm raised its target for shares to $20 from $18.
• Blackrock (BLK) was upgraded to outperform from market perform at Keefe Bruyette.
• Disney (DIS) and News Corp (NWS) were upgraded to buy from neutral at Goldman.
• Portland General Electric (POR) was upgraded to neutral from underperform at BofA/Merrill.

Analyst Upgrades

• Piper Jaffray upgraded MWI Veterinary Supply (MWIV) to overweight from neutral and raised its target for shares to $50.
• UBS believes Nokia (NOK) is well positioned for smartphone growth. The firm upgraded shares to buy from neutral and has a $19.55 price target.
• Wells Fargo upgraded Cedar Fair (FUN) to outperform from market perform. After the company's merger agreement with Apollo was terminated, the firm thinks the company will be able to refinance its debt, removing an uncertainty.
• Darden (DRI) was upgraded to outperform from neutral at Cowen.
• KeyCorp (KEY) was upgraded to buy from neutral at Goldman.
• Bank of Ireland (IRE) was upgraded to hold from sell at RBS.

Becton Dickinson (BDX), first discussed here on March 17, 2009 at a price of $65.66, remains well-positioned for the new U.S. health care era.

Look for Becton's 2010 revenue to surge 8-11% a a result of strong gains in its medical segment; diagnostics revenue should also rise substantially as demand for safety products and infectious disease/flu-related products sees steadily increasing global demand. Meanwhile, the bioservices unit revenue will likely trail the above, but still record 3-5% growth in 2010.

Analyst Upgrades

• Citigroup upgraded JPMorgan (JPM) to buy from hold on valuation as it finds the risk/reward on shares attractive following yesterday's sell-off. Citi keeps a $48 price target on the stock.
• Oppenheimer upgraded International Game Tech (IGT) to outperform from perform as it believes fundamentals for slot suppliers will improve over the next two years. The firm has a $29 price target on the stock.
• SunTrust believes Perry Ellis (PERY) is now positioned to deliver stronger margins and significant reductions in charge-backs. Shares were upgraded to buy from neutral.
• Nordstrom (JWN) was upgraded to neutral from underperform at BofA/Merrill.
• Tyson Foods (TSN) was upgraded to buy from hold at BB&T.
• Consol Energy (CNX) was upgraded to buy from neutral at Goldman.

Analyst Upgrades

• Citigroup upgraded PPG Industries (PPG) to buy from hold on expectations the company will benefit from increased auto production in 2010. The firm raised its price target on shares to $71 from $62.
• Stephens upgraded H&R Block (HRB) to overweight from equal weight as it believes the company is well positioned to gain market share with the problems at Jackson Hewitt (JTX). The firm raised its target price on H&R Block shares to $28 from $22.
• Credit Suisse raised Tyson Foods (TSN) to outperform from neutral and raised its target to $16 from $13. The firm believes Tyson is a cyclical stock in the early stages of a rebound in protein processing.
• Lennar (LEN) was upgraded to overweight from equal weight at Barclays.
• Chipotle Mexican Grill (CMG) was upgraded to market perform from underperform at Wells Fargo.
• Spartech (SEH) was upgraded to buy from hold at KeyBanc.

As expected, Becton Dickinson (BDX) has broken through resistance in the $65-70 range, hence it goes without saying I'm reiterating my buy rating for the company's shares, first recommended on March 17, 2009, at a price of $65.66. However, the call has qualifiers, so attention is advised.

In FY2010 Becton's revenue growth should total about 5% to 7%, after essentially flat revenue in FY2009. Hospital spending cutbacks will hurt, but BDX will make up with increased government orders, lower operating costs, and moderating raw material costs. Becton's medical and diagnostic units will likely register revenue growth at or above 5% to 6% in 2010; meanwhile, its bioscience unit will register more-modest gains.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"Medical equipment giant Becton, Dickinson and Co. (BDX) is our top investment pick for the coming year," says Jonas Elmerraji. Here's his review from the advisor's Rhino Stock Report.

"If anything's certain for 2010, it'll be that nothing's certain as far as stocks are concerned. With a substantial rally that's pushed the valuations of major indexes like the S&P 500 and Dow more than 60% higher since mid-March lows, it's inevitable for investor anxiety to spill over into the New Year.

Analyst Upgrades

• FBR Capital upgraded Bank of America (BAC) to outperform from market perform to reflect its positive view of the company's $20.5M common equity raise and $45B TARP repayment. The firm believes the $20.5B capital raise is lower than some expected and that Bank of America could potentially announce a new CEO by year-end. FBR raised its price target on shares to $20 from $15.
• JPMorgan upgraded Kennametal (KMT) to overweight from neutral. The firm, which has a $30 target on the stock, cites the recent pullback in shares and believes increased industrial production in 2010 could be a positive catalyst for the company.
• Credit Suisse upgraded Ternium (TX) to outperform from neutral and raised its target to $40 from $31. The firm upgraded shares based on expectations for further improvements in profitability.
• G-III Apparel (GIII) was upgraded to overweight from market weight at Thomas Weisel.
• Cubist Pharma (CBST) was raised to outperform from sector perform at RBC Capital.
• AvalonBay (AVB) was upgraded to neutral from sell at Goldman.

Analyst upgrades:

• Bernstein upgraded General Electric (NYSE: GE) to Outperform from Market Perform Thursday after the close. The firm sees an improved risk/reward on the stock and raised its price target to $19 from $18.
• Bernstein also upgraded Amazon.com (NASDAQ: AMZN) to Outperform from Market Perform as it believes sales growth and margin expansion expectations are too low. The firm raised its target on shares to $160 from $125.
• Piper Jaffray upgraded CBS (NYSE: CBS) to Neutral from Underweight following the company's Q3 results and raised its target on shares to $13 from $12.
• JPMorgan upgraded Macy's (NYSE: M) to Overweight from Neutral to reflect the company's improving comps. The firm has a $23 target on the stock.
• Ansys (NASDAQ: ANSS) was upgraded to Buy from Hold at Jefferies.
• Travelers (NYSE: TRV) was upgraded to Buy from Neutral at Goldman.
• Air Methods (NASDAQ: AIRM) was upgraded to Overweight from Equal Weight at Stephens.

Medical equipment giant Becton Dickinson's (NYSE: BDX) stock has meandered since recommended on March 17, 2009 at a price of $65.66, with volatility, most likely due to U.S. federal health care reform legislation uncertainty, but look for better quarters ahead, when the dust settles, which is why I'm reiterating my Buy rating for the company's shares.

In FY2010, Becton's revenue growth should total about 5-7%, after essentially flat revenue in FY2009. Hospital spending cutbacks will hurt, but BDX will make up for the aforementioned with increased government orders, lower operating costs, and moderating raw material costs.